Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Cools

Showing results (161-170 of 184) with videos related to

Pageof 19
Sort By:
Cancer Discovery|March 3, 2018
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia DevelopmentCharles E de Bock, Sofie Demeyer, Sandrine Degryse, et al.
Leukemia|June 23, 2018
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALLKim R Kampen, Sergey O Sulima, Benno Verbelen, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Haematologica|May 7, 2016
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implicationsValentina Gianfelici, Sabina Chiaretti, Sofie Demeyer, et al.
Leukemia|March 10, 2019
Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALLKim R Kampen, Sergey O Sulima, Benno Verbelen, et al.
Blood|October 11, 2014
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemiaSofie Peirs, Filip Matthijssens, Steven Goossens, et al.
Blood|February 24, 2019
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemiaDiego Sánchez-Martínez, Matteo L Baroni, Francisco Gutierrez-Agüera, et al.
Blood|April 20, 2021
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemiaDanika Di Giacomo, Roberta La Starza, Paolo Gorello, et al.
Leukemia|May 19, 2021
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistanceJordy C G van der Zwet, Jessica G C A M Buijs-Gladdines, Valentina Cordo', et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Pageof 19

Showing results (161-170 of 184) with videos related to

Sort By:
Pageof 19
Cancer Discovery|March 3, 2018
HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia DevelopmentCharles E de Bock, Sofie Demeyer, Sandrine Degryse, et al.
Leukemia|June 23, 2018
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALLKim R Kampen, Sergey O Sulima, Benno Verbelen, et al.
Blood|September 30, 2008
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cellsEllen Weisberg, Johannes Roesel, Guido Bold, et al.
Haematologica|May 7, 2016
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implicationsValentina Gianfelici, Sabina Chiaretti, Sofie Demeyer, et al.
Leukemia|March 10, 2019
Correction: The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALLKim R Kampen, Sergey O Sulima, Benno Verbelen, et al.
Blood|October 11, 2014
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemiaSofie Peirs, Filip Matthijssens, Steven Goossens, et al.
Blood|February 24, 2019
Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemiaDiego Sánchez-Martínez, Matteo L Baroni, Francisco Gutierrez-Agüera, et al.
Blood|April 20, 2021
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemiaDanika Di Giacomo, Roberta La Starza, Paolo Gorello, et al.
Leukemia|May 19, 2021
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistanceJordy C G van der Zwet, Jessica G C A M Buijs-Gladdines, Valentina Cordo', et al.
Cancer Cell|June 5, 2003
PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative diseaseJan Cools, Elizabeth H Stover, Christina L Boulton, et al.
Pageof 19